Chugai Pharmaceutical Co Ltd (JP:4519)
:4519
Earnings Data
Report Date
Apr 24, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
63.06Last Year’s EPS
59.09Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a strongly positive financial and operational picture: record FY2025 revenue, operating profit and margin, robust FY2026 guidance, significant clinical and pipeline progress (notably NXT007, giredestrant, Enspryng, orforglipron), and disciplined cost control. Key risks were acknowledged — a serious safety event delaying Elevidys launch, biosimilar and generic pressure on legacy products (Actemra, Avastin), several project discontinuations, and some uncertainty around royalty/milestone timing and cash reduction after special dividends. On balance the call emphasized sustained growth, high profitability and a focused R&D strategy while noting manageable but material risks that warrant monitoring.Company Guidance
Record financial results for FY2025
Revenue JPY 1,257.9 billion (exceeded initial forecast by 5.7%; Taniguchi reported +7.5% year-on-year), core operating profit JPY 623.2 billion (+12.1% YoY), operating profit margin a record 49.5%, and net income JPY 451.0 billion (+13.6% YoY).
Strong FY2026 guidance
Management projects FY2026 revenue JPY 1,345 billion (+6.9% YoY) and core operating profit JPY 670 billion (+7.5% YoY), supported by domestic product sales growth, higher royalty/profit-share income and milestone payments.
Dividend increase and shareholder returns
FY2025 total annual dividend JPY 272 per share (year-end JPY 147 including JPY 75 100th-anniversary commemorative dividend). FY2026 ordinary dividend forecast raised by JPY 10 to JPY 132; policy targets an average payout ratio of 45% based on core EPS.
Robust product sales and export performance
Pharmaceutical product sales JPY 1,077.8 billion (+8.0% YoY). Overseas pharmaceutical sales JPY 605.4 billion (+12.8% YoY), driven by strong exports of Hemlibra and Actemra; Hemlibra full-year exports ~JPY 20 billion above initial forecast and Actemra exceeded forecast by ~JPY 30 billion due to slower-than-expected biosimilar penetration.
Pipeline progress and clinical successes
Proof of concept (POC) confirmed for NXT007 and advanced to Phase III; Elevidys regulatory approval obtained; Enspryng Phase III met primary endpoint for MOGAD; orforglipron met primary endpoint in switching trial. Giredestrant clinical data: evERA showed PFS risk reduction of 62% (ESR1+ group) and 44% (ITT); lidERA interim analysis showed IDFS risk reduction of 30%.
Pipeline scale and prioritization
Pipeline streamlined for focus: Phase I projects reduced from 21 to 15 to concentrate resources; currently 9 projects in Phase II, 28 in Phase III, and 3 projects under regulatory review with approvals expected within the year.
Operational efficiency and cost control
Cost of sales increased 4.0% but pharmaceutical cost ratio improved by 1.3 percentage points to 32.6%; SG&A expenses held nearly flat at JPY 103.2 billion through efficiency efforts.
Positive capital efficiency and cash generation
Operating cash flow JPY 452.1 billion; ROIC 43.9% (up 1 percentage point YoY) and ROE 22.1%, both well above cost of capital; foreign exchange tailwind added approximately JPY 49.6 billion to revenue and JPY 44.2 billion to operating profit in FY2025.
Open innovation and global partnering expansion
12 new research and technical collaborations closed; new U.S. Partnering Office opened in South San Francisco to accelerate collaborations with academia and bioventures; strategic partnerships announced with Gero, Araris and Rani Therapeutics.
JP:4519 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JP:4519 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 29, 2026 | ¥8447.00 | ¥8309.00 | -1.63% |
Oct 24, 2025 | ¥7047.67 | ¥6831.92 | -3.06% |
Jul 24, 2025 | ¥7011.22 | ¥7130.42 | +1.70% |
Apr 24, 2025 | ¥7939.15 | ¥7994.37 | +0.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Chugai Pharmaceutical Co Ltd (JP:4519) report earnings?
Chugai Pharmaceutical Co Ltd (JP:4519) is schdueled to report earning on Apr 24, 2026, Before Open (Confirmed).
What is Chugai Pharmaceutical Co Ltd (JP:4519) earnings time?
Chugai Pharmaceutical Co Ltd (JP:4519) earnings time is at Apr 24, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Chugai Pharmaceutical Co Ltd stock?
The P/E ratio of Chugai Pharmaceutical Co is N/A.
What is JP:4519 EPS forecast?
JP:4519 EPS forecast for the fiscal quarter 2026 (Q1) is 63.06.